Scholar Rock Holding (SRRK) Short term Debt (2017 - 2024)

Scholar Rock Holding's (SRRK) quarterly Short term Debt came in at $1.6 million in Q2 2024, down 71.13% quarter-over-quarter from $5.5 million in Q1 2024.

Scholar Rock Holding (SRRK) Short term Debt (2017 - 2024) Analysis & Trends

Scholar Rock Holding's Short term Debt history runs 7 years deep, the most recent figure standing at $1.6 million for Q2 2024.

  • On a quarterly basis, Short term Debt changed N/A year-over-year to $1.6 million in Q2 2024; TTM through Jun 2024 was $1.6 million, a N/A change from a year earlier, with the FY2023 full-year figure at $1.3 million, changed N/A from the prior year.
  • Short term Debt fell to $1.6 million in Q2 2024 per SRRK's latest filing, from $5.5 million in the prior quarter.
  • Across five years, Short term Debt topped out at $11.6 million in Q2 2022 and bottomed at $805000.0 in Q3 2022.
  • The 4-year median for Short term Debt is $1.6 million (2024), against an average of $4.1 million.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Scholar Rock Holding 6.30 Bn 6.30 Bn -

Historic Data

Download Data
DateValue
Jun 30, 2024 1.59 Mn
Mar 31, 2024 5.50 Mn
Dec 31, 2023 1.33 Mn
Sep 30, 2022 805,000.00
Jun 30, 2022 11.58 Mn
Mar 31, 2022 6.58 Mn
Dec 31, 2021 1.58 Mn
Mar 31, 2019 270,000.00
Dec 31, 2018 424,000.00
Sep 30, 2018 578,000.00
Jun 30, 2018 731,000.00
Dec 31, 2017 641,000.00